Archive for the Official Press Releases Category

Lumos Pharma Acquires Candidate for Oral Treatment of Growth Hormone Deficiency

Lumos Pharma, Inc., a clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare and neglected diseases, today announced that it has acquired the license for LUM-201, an investigational orally administered small molecule that promotes secretion of growth hormone from the pituitary gland, from Ammonett Pharma LLC.  Lumos plans to initiate a...Read More

LUMOS PHARMA APPOINTS CAROL A. DUTCH AS SENIOR DIRECTOR, PATIENT ENGAGEMENT

Austin, Texas – June 21, 2016 – Lumos Pharma, Inc. has further expanded its management team with the appointment of Carol A. Dutch as Senior Director, Patient Engagement. Ms. Dutch will create and lead global patient engagement projects to support the clinical development and pre-commercial phases of Lumos’ rare and orphan disease pipeline projects. Over...Read More

Lumos Pharma Appoints John C. McKew, Ph.D. Chief Scientific Officer

Austin, Texas – April 20, 2016 – Lumos Pharma, Inc. a clinical stage biotechnology company focused on bringing novel therapies to patients with unmet medical needs in severe, rare, and genetic diseases, announced that John C. McKew, Ph.D. has joined the company as its Chief Scientific Officer. “John is one of the most well-known and...Read More

Lumos Pharma Appoints David M. Weiner, M.D. as Chief Medical Officer

Austin, Texas – April 13, 2016 –  Lumos Pharma, Inc., a biotechnology company focused on bringing novel therapies to patients with unmet medical needs in severe, rare, and genetic diseases, announced that David M. Weiner, M.D. has joined the company as its Chief Medical Officer. “Dave’s accomplishments in the pharmaceutical industry and extensive clinical experience...Read More

Lumos Pharma Raises $34 Million in Series B Financing

AUSTIN, Texas – April 6, 2016 – Lumos Pharma, a biotechnology company focused on developing therapeutics for orphan diseases, announced the successful completion of a $34 million Series B financing.  Lumos will use the proceeds for clinical trials and commercialization of its lead compound, LUM-001, for the treatment of Creatine Transporter Deficiency (CTD). Funding will...Read More